Skip to main
AARD

AARD Stock Forecast & Price Target

AARD Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 11%
Hold 22%
Sell 11%
Strong Sell 0%

Bulls say

Aardvark Therapeutics is experiencing challenges with their clinical trial for ARD-101, which has been placed on hold by the FDA due to a QRS signal. Management has stated that a new trial will be required, and success for the company relies on understanding the cause of the signal, showing positive efficacy data, and securing a viable path for registration within their cash runway. Given the lack of clarity and uncertainties, it is prudent to remain neutral on Aardvark Therapeutics.

Bears say

Aardvark Therapeutics is currently facing significant risks due to pausing patient enrollment and dosing in its pivotal HERO trial due to reversible cardiac observations at above-target therapeutic doses. This could potentially lead to delays in obtaining regulatory approval and launching its product candidate ARD-101, as well as potential partnership and dilution risks. Without further clarity on the future prospects of ARD-101, it is difficult to estimate the company's potential valuation and outlook.

AARD has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 11% recommend Buy, 22% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aardvark Therapeutics Inc (AARD) Forecast

Analysts have given AARD a Buy based on their latest research and market trends.

According to 9 analysts, AARD has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aardvark Therapeutics Inc (AARD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.